Histone deacetylase inhibitor trichostatin a enhances antitumor effects of docetaxel or erlotinib in A549 cell line

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3471-3476

  Zhang, Qun Cheng ^a   Jiang, Shu Juan ^a,b   Zhang, Song ^b   Ma, Xiao Bin ^b  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Docetaxel; Epidermal growth factor receptor; Erlotinib; Hsp90; Trichostatina; Tubulin

Indexed keywords

EID: 84873675746     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3471     Document Type: Article

References (26)

1. Blagosklonny MV, Robey R, Sackett DL, et al (2002). Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther, 1, 937-41.
2. Cheng DD, Yang QC, Zhang ZC, et al (2012). Antitumor activity of histone deacetylase inhibitor trichostatin a in osteosarcoma cells. Asian Pac J Cancer Prev, 13, 1395-9.
3. Dowdy SC, Jiang S, Zhou XC, et al (2006). Histone deacetylase inhibitiors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol cancer ther, 5, 2767-76.
4. Edwards A, Li J, Atadja P, et al (2007). Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther, 6, 2515-24.
5. Egger G, Liang G, Aparicio A, et al (2004). Epigenetics in human disease and prospects for epigenetic therapy. Nature, 429, 457-63.
6. Esteller M (2002). CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene, 21, 5427-40.
7. GiacconeG (2005). Epidermal growth factor receptor inhibitors in the treatment of non- small cell lung cancer. Clin Oncol, 23, 3235-42.
8. Giommarelli C, Zuco V, Favini E, et al (2010). The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci, 67, 995-1004
9. Hajji N, Wallenborg K, Vlachos P, et al (2008). Combinatorial action of the HDAC inhibitor trichostatinA and etoposide induces caspase -mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. Oncogene, 27, 3134-44.
10. Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 5, 341-54.
11. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics, 2008. CA Cancer J Clin, 58, 71-96.
12. Jiang S, Dowdy SC, Meng XW, et al (2007). Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells. Gynecol Oncol, 105, 493-500.
13. Jones PA, BaylinSB (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet, 3, 415-28.
14. Kim SH, Kang HJ, Na H, et al (2010). Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein. Breast Cancer Res, 12, R22.
15. Labourey JL, Cupissol D, Calais G, et al (2007). Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol, 30, 278-82.
16. Liu T, Zhang M, Zhang H, et al (2008). Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol, 587, 78-84.
17. Liu YL, Zhang YL, Fu JH, et al (2011). Chemotherapeutic effects of different paclitaxel plus poldine combination methods for treatment of ovarian carcinoma. Asian Pac J Cancer Prev, 12, 1713-6.
18. Long N, Moore MA, Chen W, et al (2010).Cancer epidemiology and control in north-East Asia - past, present and future. Asian Pac J Cancer Prev, 11, 107-48.
19. 2/M transition, slippage of spindle check-point, and cell death in a transcription-dependent manner. Biochem Biophys Res Commun, 378, 326-31.
20. Ozaki K, Kosugi M, Baba N, et al (2010). Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem Biophys Res Commun, 391, 1610-5.
21. Pao W, Miller VA, Politi KA, et al (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoSMed, 2, 225-35.
22. Powers MV, Workman P(2007). Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett, 581, 3758-69.
23. Ranganathan P, Rangnekar VM(2005). Exploiting the TSA connections to overcome apoptosis-resistance. Cancer BiolTher, 4, 391-2.
24. Scroggins BT, Robzyk K, Wang D, et al (2007). An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell, 25, 151-9.
25. Sharma P, Kumar S, Kundu GC (2010). Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol Cancer, 9, 178.
26. Sun S, Schiller JH, Gazdar AF (2007). Lung cancer in never smokers-a different disease. Nat Rev Cancer, 7, 778-90.